

Manuscripts

Conjeevaram HS, Fried MW, Jeffers LJ, Terrault N, Wiley-Lucas TW, Afdhal N, Brown RS, Belle SH, Robuck PR, Howell CD. Peginterferon alfa-2a and ribavirin in african american and caucasian patients with chronic hepatitis c genotype 1. *Gastroenterology* 2006;131:470–477

Published Abstracts and Presentations

Belle SH, Conjeevaram HS, Jeffers LJ. (2003 October) Racial differences in patients with hepatitis C genotype 1. (Poster) AASLD, Boston MA. *Hepatology*(38):4 - Suppl 1, p. 309A.

Burton JR, Klarquist J, IM K, Belle SH, Rosen HR. (2006 May) Stronger Baseline HCV-specific immunity is associated with a higher likelihood of sustained virologic response to combination antiviral therapy of chronic hepatitis C. (Poster) DDW, Los Angeles, CA.

Conjeevaram HS, Fried MW, Jeffers LJ, Terrault N, Wiley-Lucas TW, Afdhal N, Brown RS, Belle SH, Robuck PR, Howell CD. (2005 November) Peginterferon alfa-2a and ribavirin in african american and caucasian patients with chronic hepatitis c genotype 1. (Presentation) AASLD, San Francisco, CA. *Hepatology* (42):4 - Suppl 1, p. 275A.

Conjeevaram HS, Wahed A, Burant C. (2005 May) Insulin resistance is independent of hepatic steatosis and is augmented by environmental factors such as obesity in patients with HCV genotype 1 infection. (Poster) DDW, Chicago, IL.

Conjeevaram HS, Kleiner DE, Everhart JE, Afdhal N, Brown RS, Fried MW, Howell CD, Jeffers LJ, Terrault N, Wiley TE, Cherry CR, Wahed AS. (2004 October) Race, insulin resistance, visceral adiposity and hepatic steatosis in patients with chronic hepatitis C. (Poster) AASLD, Boston MA. *Hepatology* (40):4 - Suppl 1, p. 443A.

Conjeevaram HS, Kleiner DE, Afdhal N, Brown RS, Fried MW, Howell CD, Jeffers LJ, Terrault N, Wiley TE, Cherry C, Belle SH, Hoofnagle JH. (2003 October) Race, insulin resistance, visceral adiposity and hepatic steatosis in genotype 1 patients with chronic hepatitis C. (Poster) AASLD, Boston MA. *Hepatology* (38):4 - Suppl 1, p. 347A.

Grosse WM, Taylor MW, Sanda C, Weizel P, Edenberg HJ, Stephens M, McClintick J. (2004 July) Chronic hepatitis C infection: patient gene regulation in response to combined PEG-Interferon/ribavirin drug treatment. Amer. Soc. of Virology, Montreal, Quebec.

Howell C, Dowling T, Jeffers L, Taylor M, Terrault N, Wiley-Lucas T, Haritos M. (2006 May) Relationship between serum peginterferon and 2,5 OAS kinetics and virologic responses in african american and caucasian patients with chronic hepatitis C, genotype 1 during peginterferon combination therapy. (Presentation) DDW, Los Angeles CA.

Howell C, Dowling T, Jeffers L, Terrault N, Wiley-Lucas T, Haritos M. (November 2005) Peginterferon alfa-2a pharmacokinetics in african american and caucasian americans infected with HCV genotype 1. (Poster) AASLD, San Francisco, CA. *Hepatology* (42):4 - Suppl 1, p. 658A.

Kelley S, Cline J, Lawlor S, Smith S. (2005 May) Development of a retention protocol to target participant subgroups in a multi-center clinical trial. (Poster) Society for Clinical Trials, Portland, OR. *Clinical Trials*(2):1Suppl - p. S80.

Lawlor S, Cai C, Kelley S, Belle S. (2003 July) An automated serious adverse event reporting system. (Oral Presentation) Society for Clinical Trials, London, England. *Controlled Clinical Trials*(24):3Suppl - p. 46S-47S.

Lawlor S, Kelley S, Belle S. (2003 July) Self-assessments using touch screen technology. (Poster) Society for Clinical Trials, London, England. *Controlled Clinical Trials* (24):3Suppl - p. 119S.

Rhodes SL, Erlich H, Im KA, Wang J, Li J, Bugawan T, Jeffers L, Tong X, Su X, Yee LJ, Liang TJ, Yang H. (2006 May) Association between HLA alleles A*03, B*58, DPB1*1701 and sustained virologic response to pegylated interferon and ribavirin therapy in chronic HCV, genotype 1-infected, treatment naïve caucasian and african americans. DDW, Los Angeles, CA.

Rosen HR, Weston SJ, Im K, Belle SH. (2004 October) Ethnicity and the cellular immune response in patients with chronic hepatitis C genotype 1 infection. (Oral Presentation) AASLD, Boston MA. *Hepatology* (40):4 - Suppl 1, p. 178A.

Smith SR, Belle SH, Brown RS, Theodore D, Fried MW. (2003 October) Baseline psychosocial characteristics of participants in the Virahep-C study. (Poster) AASLD, Boston MA. *Hepatology*(38):4 - Suppl 1, p. 313A.

Su X, Rhodes SL, Yee LJ, Im KA, Tong X, Howell C, Haritos M, Liang TJ, Taylor MW, Yang H. (2006 May) Association of interferon signaling pathway and interferon stimulated genes with response to pegylated interferon and ribavirin therapy in HCV infected caucasian and african american patients. (Presentation) DDW, Los Angeles, CA.

Taylor MW, Edenberg HJ, Tsukahara T, Stephens M, McClintick J, Lan L. (2005 June) Distinct differences in interferon-induced gene response between patients resistant to interferon/ribavirin therapy and those showing early viral clearance. (Oral Presentation) Exploring the Functional Genomics and Proteomics of Liver in Health and Disease, Warrenton, VA.

Taylor MW, Schaley J, Edenberg HJ, Tsukahara T, Rubinstein A, Stephens M. (2004 October) Distinct differences in gene response between patients resistant to interferon/ribavirin therapy and those showing early virus clearance. 11th International Symposium on Hepatitis C & Related Viruses, Heidelberg, Germany.

Taylor MW, Edenberg HJ, Tsukahara T, Stephens M. (2004 October) Global analysis of genes induced by interferon and ribavirin in hepatitis C patients. Int'l. Society of Cytokine and Interferon Research, Puerto Rico.

Wahed A, Im K, Wiley TE, Belle SH. (2004 August) HCV viral dynamics. (Poster) Joint Statistical Meetings, Toronto, Canada.

Yee LJ, Tang YM, Im K, Kleiner DE, Wang D, Wahed A, Tong X, Fontana R, Liang TJ, Yang H. (2005 May) Genetic variation in an interferon-stimulated gene, myxovirus-1 (MxA), has a significant protective effect from fibrosis in genotype 1 chronic hepatitis C virus infection. (Oral Presentation) DDW, Chicago, IL.

Related Journal Publications

Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, **Tavis JE, Rosen HR.** (2005) Immune evasion versus recovery following acute hepatitis C virus infection from a shared source. *J. Ex. Med.* In Press.

Ermei Y, Tavis JE. A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. *Virology Journal* 2005,2:88

Related Abstracts and Presentations

Cannon NA, Metzger LM, Donlin MJ, Lyra A, Yao E, DiBisceglie AM, **Tavis JE**. (2004 October) Genetic and biochemical evidence for action of ribavirin through the HCV RNA polymerase in vivo. (Poster) 11th International Symposium on Hepatitis C & Related Viruses, Heidelberg, Germany.

Related Projects

Howell, Charles D. Predicting Outcomes of Peginterferon & HCV. Grant # - 5R01DK066920-2. May 2004 - February 2007.

Yee, Leland. Host genetic determinants of HCV viral dynamics. Grant # - 1K12-HD049109-01. Funding approved, July 2005.